Last €0.96 EUR
Change Today +0.158 / 19.68%
Volume 171.3K
VSC On Other Exchanges
As of 8:15 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

4sc ag (VSC) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/4/13 - €1.94
52 Week Low
10/20/14 - €0.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 4SC AG (VSC)

Related News

No related news articles were found.

4sc ag (VSC) Related Businessweek News

No Related Businessweek News Found

4sc ag (VSC) Details

4SC AG researches and develops small-molecule drugs for the treatment of cancer and autoimmune diseases. The company operates through two segments, Development and Discovery & Collaborative Business. Its product portfolio in the area of autoimmune includes Vidofludimus, an orally administered small-molecule drug, which is in Phase II b clinical trial for the treatment of crohn’s diseases. The company’s product portfolio in the area of oncology comprises Resminostat, an oral pan-histone-deacetylase inhibitor, which is in Phase II and Phase I clinical trials for the treatment of liver cancer, hodgkin lymphoma, colorectal cancer, non-small-cell lung cancer, and solid tumors; 4SC-202, an epigenetic anti-cancer compound that is in Phase I clinical trials for the treatment of hematologic tumors; and 4SC-205, an anti-cancer compound, which is in Phase I clinical trials for the treatment of solid tumors. It also conducts research programs in the areas of cancer immunotherapy, cancer stem cells, epigenetics, cytokine modulation, and ion channel blockers for the treatment of autoimmune, inflammatory eye, and oncology diseases. The company was founded in 1997 and is headquartered in Martinsried, Germany.

55 Employees
Last Reported Date: 08/8/14
Founded in 1997

4sc ag (VSC) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €278.0K
Co-Founder, Chief Scientific Officer, Chief D...
Total Annual Compensation: €198.0K
Compensation as of Fiscal Year 2013.

4sc ag (VSC) Key Developments

US Patent Office Grants Patent Protection to 4SC AG for its Resminostat

4SC AG announced that the company has further strengthened the patent protection for its anti-cancer compound resminostat. The US Patent Office has granted the patent for resminostat's manufacturing process. The patent, which runs until 20 July 2029, protects the chemical process used in the manufacture of resminostat. This constitutes an additional obstacle for potential competitors while further extending the total term of resminostat's portfolio of property rights. Overall, this means the resminostat manufacturing process is protected until 2029 in almost all key markets around the world, including Europe, Japan, China, Russia, Hong Kong, Singapore and Australia and now the USA.

4SC AG Announces Board Changes, Effective 18 September 2014

4SC AG announced that Dr. Thomas Werner and Klaus Khn have informed the company that they will resign from their positions as members of the Supervisory Board of 4SC AG for personal reasons effective at the end of 18 September 2014.

4SC Reports Earnings Results for the Second Quarter and Six Months of 2014; Provides Earnings Guidance for the Year 2014

4SC reported earnings results for the second quarter and six months of 2014. For the quarter, the company narrowed net loss by 45% to EUR 1.85 million the back of lower operating expenses and increased revenues. Revenue more than doubled to EUR 2.54 million in the reporting period. For the six months, the company net loss went down by 35% to EUR 4 million, while revenue doubled to EUR 4 million. Based on current revenue, expense planning and current funds of EUR 3.42 million, the company confirmed its annual guidance for achieving a short-term flow of funds and lower net loss for the full year of 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSC:GR €0.96 EUR +0.158

VSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSC.
View Industry Companies

Industry Analysis


Industry Average

Valuation VSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.7x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4SC AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at